Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR1015 (Fimasartan + Indapamide) vs Co-administered Components in Healthy Volunteers (Fed)
NCT06744439Phase 1Completed
- Sponsor
- Boryung
- Start
- Jan 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fimasartan and indapamide in essential hypertension (2 arms), sponsored by Boryung. Primary endpoints: Area under the concentration-time curve from time zero to time τ and Maximum concentration of drug in plasma. Started Jan 2025; status: completed.
02
Drugs
fimasartanindapamide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06744439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744439.